title: Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study.
abstract: When applying survival analysis, such as Cox regression, to data from major clinical trials or other studies, often only baseline covariates are used. This is typically the case even if updated covariates are available throughout the observation period, which leaves large amounts of information unused. The main reason for this is that such time-dependent covariates often are internal to the disease process, as they are influenced by treatment, and therefore lead to confounded estimates of the treatment effect. There are, however, methods to exploit such covariate information in a useful way. We study the method of dynamic path analysis applied to data from the Swiss HIV Cohort Study. To adjust for time-dependent confounding between treatment and the outcome 'AIDS or death', we carried out the analysis on a sequence of mimicked randomized trials constructed from the original cohort data. To analyze these trials together, regular dynamic path analysis is extended to a composite analysis of weighted dynamic path models. Results using a simple path model, with one indirect effect mediated through current HIV-1 RNA level, show that most or all of the total effect go through HIV-1 RNA for the first 4 years. A similar model, but with CD4 level as mediating variable, shows a weaker indirect effect, but the results are in the same direction. There are many reasons to be cautious when drawing conclusions from estimates of direct and indirect effects. Dynamic path analysis is however a useful tool to explore underlying processes, which are ignored in regular analyses.
authors.affiliation: Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Norway. kjetil.roysland@medisin.uio.no
authors.forename: Kjetil
authors.initials: K
authors.lastname: Røysland
authors.forename: Jon Michael
authors.initials: JM
authors.lastname: Gran
authors.forename: Bruno
authors.initials: B
authors.lastname: Ledergerber
authors.forename: Viktor
authors.initials: V
authors.lastname: von Wyl
authors.forename: James
authors.initials: J
authors.lastname: Young
authors.forename: Odd O
authors.initials: OO
authors.lastname: Aalen
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D056808:Biostatistics; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015331:Cohort Studies; D016208:Databases, Factual; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D006801:Humans; D016014:Linear Models; D015233:Models, Statistical; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016019:Survival Analysis; D013557:Switzerland / Q000453:epidemiology